Yichun Wang1, Mengting Li1, Yingying Zhang1, Fengzhen Zhang1, Chunbao Liu1, Yiling Song1, Yongxue Zhang1, Xiaoli Lan2. 1. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: LXL730724@hotmail.com.
Abstract
INTRODUCTION: 18F-5-fluoro-N-(2-(Diethylamino)ethyl)picolinamide (18F-5-FPN) is a new positron-emission tomography (PET) radiopharmaceutical with potential for the detection of lymph node (LN) and pulmonary metastatic lesions of melanoma. We compared its performance with that of 18F-deoxyglucose (18F-FDG). METHODS: Cervical LN and lung melanoma metastasis models were established in C57BL/6 mice. Primary tumors were created by injection of melanoma cells into the pinna, and the resulting cervical LN metastases were evaluated. Lung metastases were created by intravenous injection of melanoma cells. The mice underwent 18F-FDG and 18F-5-FPN positron emission tomography (PET) imaging. A biodistribution study was conducted after imaging. Histopathologic evaluation of the tumors was also performed. RESULTS: LN metastases with a diameter<1cm were more visible on 18F-5-FPN PET imaging than 18F-FDG imaging. Quantitative analysis showed that the uptake of 18F-5-FPN was significantly higher than that of 18F-FDG, with values of 13.29±3.80% ID/g and 7.24±1.95% ID/g (n=5, P<0.05), respectively. LN-to-muscle ratios were 21.23±6.02 and 4.50±2.11 (n=5, P<0.01) for 18F-5-FPN and 18F-FDG, respectively. Biodistribution results were similar, with high uptake of 18F-5-FPN in the LN. 18F-5-FPN imaging manifested the pulmonary lesions clearly, while the 18F-FDG imaging showed no uptake in lesions <2mm. The related uptakes of 18F-5-FPN and 18F-FDG were 3.12±1.17% ID/g and 1.48±0.15% ID/g, respectively (n=5, P<0.05), with lung metastasis-to-muscle ratios of 8.16±3.12 and 1.28±0.18 (n=5, P<0.01), respectively. H&E and Prussian blue staining displayed pluri nucleated or mega nucleus cells and dark brown granules in the metastatic tissues, characteristic of melanoma. CONCLUSIONS: 18F-5-FPN targeted small metastatic lesions with a higher target-to-normal ratio of uptake than those of 18F-FDG, which suggests its ability to detect metastatic lesions earlier than 18F-FDG. Further studies with a wide range of melanoma cell lines should be needed to confirm the similar performance.
INTRODUCTION:18F-5-fluoro-N-(2-(Diethylamino)ethyl)picolinamide (18F-5-FPN) is a new positron-emission tomography (PET) radiopharmaceutical with potential for the detection of lymph node (LN) and pulmonary metastatic lesions of melanoma. We compared its performance with that of 18F-deoxyglucose (18F-FDG). METHODS: Cervical LN and lung melanoma metastasis models were established in C57BL/6 mice. Primary tumors were created by injection of melanoma cells into the pinna, and the resulting cervical LN metastases were evaluated. Lung metastases were created by intravenous injection of melanoma cells. The mice underwent 18F-FDG and 18F-5-FPN positron emission tomography (PET) imaging. A biodistribution study was conducted after imaging. Histopathologic evaluation of the tumors was also performed. RESULTS: LN metastases with a diameter<1cm were more visible on 18F-5-FPN PET imaging than 18F-FDG imaging. Quantitative analysis showed that the uptake of 18F-5-FPN was significantly higher than that of 18F-FDG, with values of 13.29±3.80% ID/g and 7.24±1.95% ID/g (n=5, P<0.05), respectively. LN-to-muscle ratios were 21.23±6.02 and 4.50±2.11 (n=5, P<0.01) for 18F-5-FPN and 18F-FDG, respectively. Biodistribution results were similar, with high uptake of 18F-5-FPN in the LN. 18F-5-FPN imaging manifested the pulmonary lesions clearly, while the 18F-FDG imaging showed no uptake in lesions <2mm. The related uptakes of 18F-5-FPN and 18F-FDG were 3.12±1.17% ID/g and 1.48±0.15% ID/g, respectively (n=5, P<0.05), with lung metastasis-to-muscle ratios of 8.16±3.12 and 1.28±0.18 (n=5, P<0.01), respectively. H&E and Prussian blue staining displayed pluri nucleated or mega nucleus cells and dark brown granules in the metastatic tissues, characteristic of melanoma. CONCLUSIONS:18F-5-FPN targeted small metastatic lesions with a higher target-to-normal ratio of uptake than those of 18F-FDG, which suggests its ability to detect metastatic lesions earlier than 18F-FDG. Further studies with a wide range of melanoma cell lines should be needed to confirm the similar performance.
Authors: Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz Journal: Cancers (Basel) Date: 2022-06-27 Impact factor: 6.575
Authors: Laetitia Vercellino; Dorine de Jong; Laurent Dercle; Benoit Hosten; Brian Braumuller; Jeeban Paul Das; Aileen Deng; Antoine Moya-Plana; Camry A'Keen; Randy Yeh; Pascal Merlet; Barouyr Baroudjian; Mary M Salvatore; Kathleen M Capaccione Journal: Diagnostics (Basel) Date: 2022-04-29